Related Experiment Video
Updated: Jan 1, 2026
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
Discovering novel P38α inhibitors for the treatment of prostate cancer through virtual screening methods
Kaiwen Li1,2, Zean Li1,2, Yiran Tao1,2
1Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510220, PR China.
Abstract:
Aim: P38α plays a crucial role in the development of castration-resistant prostate cancer. Discovering novel inhibitors of P38α offers potential for the development of new anticancer drugs. Methods & results: Compounds from the Chemdiv and Enamine virtual libraries were filtered to construct the P38α inhibitor-like library. A total of 58 new P38α inhibitors were discovered via virtual screening; these included three compounds (compound 1, 5, 9) with kinase IC50 of below 10 μM. In vitro, these three compounds have the potential to suppress the viabilities of prostate cancer cell lines, however, only compound 9 can inhibit the proliferation and migration of prostate cancer cells. Conclusion: The potent compounds discovered in this study demonstrate anticancer functions by targeting the P38α mitogen-activated protein kinases signaling pathway and are worthy of further investigation.
Insights
Researchers identified novel P38α inhibitors for castration-resistant prostate cancer. Compound 9 effectively suppressed prostate cancer cell proliferation and migration, showing promise as an anticancer drug candidate.
Area of Science:
- Oncology
- Medicinal Chemistry
- Molecular Biology
Background:
- P38α kinase is critical in castration-resistant prostate cancer progression.
- Targeting P38α presents a therapeutic strategy for prostate cancer.
Purpose of the Study:
- To discover novel P38α inhibitors.
- To evaluate their potential as anticancer agents for prostate cancer.
Main Methods:
- Virtual screening of compound libraries (Chemdiv, Enamine) to identify P38α inhibitor-like compounds.
- In vitro assays to assess compound efficacy on prostate cancer cell lines.
Main Results:
- Identified 58 novel P38α inhibitors, with three compounds (1, 5, 9) exhibiting IC50 below 10 μM.
- Compounds 1, 5, and 9 showed potential to suppress prostate cancer cell viability.
- Compound 9 uniquely inhibited prostate cancer cell proliferation and migration.
Conclusions:
- The discovered compounds target the P38α mitogen-activated protein kinases pathway.
- Compound 9 demonstrates significant anticancer functions and warrants further investigation for prostate cancer treatment.
